Baseline demographics and clinical characteristics of donors and patients with COVID-19 or ARDS-influenza who provided lung tissue specimens at autopsy
Patient . | Age, y . | Sex . | Background . | Ventilation, d . | Anticoagulant . |
---|---|---|---|---|---|
COVID-19 | |||||
1 | 82 | Male | Diffuse alveolar damage | 0 | Heparin |
2 | 77 | Male | Diffuse alveolar damage | 2 | Heparin |
3 | 72 | Male | Diffuse alveolar damage | 6 | Heparin |
4 | 65 | Male | Diffuse alveolar damage | 33 | Heparin |
5 | 79 | Female | Diffuse alveolar damage | 2 | Heparin |
ARDS-influenza | |||||
1 | 67 | Male | CAP | 6 | Heparin |
2 | 72 | Male | CAP | 10 | Heparin |
3 | 77 | Male | CAP | 5 | Heparin |
4 | 81 | Female | CAP | 10 | Heparin |
5 | 80 | Female | CAP | 3 | Heparin |
Donor | |||||
1 | 82 | Female | Recurrent myocardial infarction | 0 | No |
2 | 75 | Female | Heart and lung failure | 0 | Heparin |
3 | 64 | Male | Myocardial infarction | 0 | Heparin |
4 | 77 | Female | Dilated cardiomyopathy (right) | 0 | Heparin |
5 | 75 | Male | Dilated cardiomyopathy (right) | 0 | Heparin |
Patient . | Age, y . | Sex . | Background . | Ventilation, d . | Anticoagulant . |
---|---|---|---|---|---|
COVID-19 | |||||
1 | 82 | Male | Diffuse alveolar damage | 0 | Heparin |
2 | 77 | Male | Diffuse alveolar damage | 2 | Heparin |
3 | 72 | Male | Diffuse alveolar damage | 6 | Heparin |
4 | 65 | Male | Diffuse alveolar damage | 33 | Heparin |
5 | 79 | Female | Diffuse alveolar damage | 2 | Heparin |
ARDS-influenza | |||||
1 | 67 | Male | CAP | 6 | Heparin |
2 | 72 | Male | CAP | 10 | Heparin |
3 | 77 | Male | CAP | 5 | Heparin |
4 | 81 | Female | CAP | 10 | Heparin |
5 | 80 | Female | CAP | 3 | Heparin |
Donor | |||||
1 | 82 | Female | Recurrent myocardial infarction | 0 | No |
2 | 75 | Female | Heart and lung failure | 0 | Heparin |
3 | 64 | Male | Myocardial infarction | 0 | Heparin |
4 | 77 | Female | Dilated cardiomyopathy (right) | 0 | Heparin |
5 | 75 | Male | Dilated cardiomyopathy (right) | 0 | Heparin |
CAP, community-acquired pneumonia.